ODTX vs OLMA: fair value comparison
Odyssey Therapeutics, Inc. and Olema Pharmaceuticals, Inc. · Updated 2026-10-19
ODTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. OLMA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ODTX currently ranks higher by quality score.
| ODTX | OLMA | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $17.17 | $6.58 |
| 12-month range | $16.42–$24.50 | $6.58–$35.83 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #258 of 301 Healthcare | #259 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: ODTX fair value analysis · OLMA fair value analysis